Open Access
Open access
volume 26 issue 1 pages 103-109

Neurodegenerative diseases associated with mitochondrial DNA mutations.

Olga A. Zhunina 1
Andrey V. Grechko 2
Shaw-Fang Yet 3
I. Sobenin 4
Alexander N. Orekhov 5
Nikita G. Yabbarov 1
Igor A Sobenin 4
1
 
Russian Research Center for Molecular Diagnostics and Therapy, Simferopolsky Blvd., 8, 117149, Moscow, Russian Federation
3
 
Institute of Cellular and System Medicine, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 35053, Taiwan
Publication typeJournal Article
Publication date2019-11-22
scimago Q2
wos Q2
SJR0.611
CiteScore5.9
Impact factor2.8
ISSN13816128, 18734286
Drug Discovery
Pharmacology
Abstract
Mitochondrial dysfunction underlies several human chronic pathologies, including cardiovascular disorders, cancers and neurodegenerative diseases. Impaired mitochondrial function associated with oxidative stress can be a result of both nuclear and mitochondrial DNA (mtDNA) mutations. Neurological disorders associated with mtDNA mutations include mitochondrial encephalomyopathy, chronic progressive external ophthalmoplegia, neurogenic weakness, and Leigh syndrome. Moreover, mtDNA mutations were shown to play a role in the development of Parkinson and Alzheimer's diseases. In this review, the discuss the current knowledge on the distribution and possible roles of mtDNA mutations in the onset and development of various neurodegenerative diseases, with special focus on Parkinson and Alzheimer's diseases.
Found 
Found 

Top-30

Journals

1
Current Pharmaceutical Design
1 publication, 9.09%
Future Journal of Pharmaceutical Sciences
1 publication, 9.09%
Molecular Biology Reports
1 publication, 9.09%
Mitochondrion
1 publication, 9.09%
Diagnostics
1 publication, 9.09%
EMBO Journal
1 publication, 9.09%
Biochemistry (Moscow)
1 publication, 9.09%
Genes and Diseases
1 publication, 9.09%
Antioxidants
1 publication, 9.09%
1

Publishers

1
2
3
Springer Nature
3 publications, 27.27%
Elsevier
3 publications, 27.27%
MDPI
2 publications, 18.18%
Bentham Science Publishers Ltd.
1 publication, 9.09%
Pleiades Publishing
1 publication, 9.09%
1
2
3
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
11
Share
Cite this
GOST |
Cite this
GOST Copy
Zhunina O. A. et al. Neurodegenerative diseases associated with mitochondrial DNA mutations. // Current Pharmaceutical Design. 2019. Vol. 26. No. 1. pp. 103-109.
GOST all authors (up to 50) Copy
Zhunina O. A., Yabbarov N. G., Grechko A. V., Yet S., Sobenin I., Orekhov A. N., Yabbarov N. G., Sobenin I. A. Neurodegenerative diseases associated with mitochondrial DNA mutations. // Current Pharmaceutical Design. 2019. Vol. 26. No. 1. pp. 103-109.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.2174/1381612825666191122091320
UR - https://doi.org/10.2174/1381612825666191122091320
TI - Neurodegenerative diseases associated with mitochondrial DNA mutations.
T2 - Current Pharmaceutical Design
AU - Zhunina, Olga A.
AU - Yabbarov, Nikita G
AU - Grechko, Andrey V.
AU - Yet, Shaw-Fang
AU - Sobenin, I.
AU - Orekhov, Alexander N.
AU - Yabbarov, Nikita G.
AU - Sobenin, Igor A
PY - 2019
DA - 2019/11/22
PB - Bentham Science Publishers Ltd.
SP - 103-109
IS - 1
VL - 26
PMID - 31755379
SN - 1381-6128
SN - 1873-4286
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2019_Zhunina,
author = {Olga A. Zhunina and Nikita G Yabbarov and Andrey V. Grechko and Shaw-Fang Yet and I. Sobenin and Alexander N. Orekhov and Nikita G. Yabbarov and Igor A Sobenin},
title = {Neurodegenerative diseases associated with mitochondrial DNA mutations.},
journal = {Current Pharmaceutical Design},
year = {2019},
volume = {26},
publisher = {Bentham Science Publishers Ltd.},
month = {nov},
url = {https://doi.org/10.2174/1381612825666191122091320},
number = {1},
pages = {103--109},
doi = {10.2174/1381612825666191122091320}
}
MLA
Cite this
MLA Copy
Zhunina, Olga A., et al. “Neurodegenerative diseases associated with mitochondrial DNA mutations..” Current Pharmaceutical Design, vol. 26, no. 1, Nov. 2019, pp. 103-109. https://doi.org/10.2174/1381612825666191122091320.